Intravenous saline and amino acid drug supplies should begin to increase in the next few weeks as manufacturing facilities in Puerto Rico ramp up production, Food and Drug Administration Commissioner Scott Gottlieb, M.D., said yesterday in an update on the shortages. “Just before the holidays, Baxter – a leading producer of IV saline fluids – announced that all their facilities on the island have returned to the commercial power grid,” Gottlieb said. “Moreover, all the other companies that manufacture products that were on our initial list of drugs that we considered critical and at risk of potential shortages – because the drugs were largely or entirely manufactured in Puerto Rico – are now on the power grid. Many of these companies report to us that their production is increasing. While there are still many challenges that remain – for instance, the commercial power grid remains unstable in places – these developments reduce the risk of any future shortages resulting from the impact of the storm on the island’s manufacturing sector.” AHA has urged FDA and Congress to do more to address the drug shortages, and worked with FDA and the Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response to update members on the issue.

Related News Articles

Chairperson's File
Public
Most hospitals and health systems are the largest organizations in our communities, providing critical services needed by every one of our neighbors. We take…
Headline
The AHA May 16 urged the Department of Commerce to consider tariff exceptions for critical minerals and derivative products used for medical purposes. Critical…
Headline
The AHA May 14 urged the Senate Finance Committee to take steps to strengthen the supply chain for essential pharmaceutical and other medical products. In…
Headline
The U.S. and China reached a joint agreement to temporarily reduce tariffs for 90 days, the White House announced May 12. Both countries will lower tariffs by…
Headline
The AHA May 12 responded to the Office of Management and Budget's April 11 request for information on regulatory relief, making 100 suggestions to the Trump…
Headline
AHA today submitted comments to the Department of Commerce on its Section 232 national security investigation of pharmaceutical and pharmaceutical ingredients…